Visit Healthesystems in booth #824 as we exhibit at RISKWORLD, a conference for risk management professionals.
Healthesystems is attending the NCCI Annual Insights Symposium, which brings together senior thought leaders in workers' comp.
Approval Date: Mar 2024
Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure
Approval Date: Feb 2024
A biosimilar to Humira, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis
Approval Date: Feb 2024
Indicated for the treatment of HIV-1 infection
Approval Date: Feb 2024
Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate
Approval Date: Dec 2023
Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily
Approval Date: Nov 2023
Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity
Approval Date: Nov 2023
Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes
Approval Date: Nov 2023
Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis
Approval Date: Oct 2023
Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously
Approval Date: Oct 2023
A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis
Approval Date: Oct 2023
A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe ulcerative colitis
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Approval Date: Oct 2023
Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation
